

## 17. Cilt Dizini 17<sup>th</sup> Volume Index

### KONU DİZİNİ (Mart 2011-Aralık 2011)

#### A-B

Alzheimer hastalığı, 181-184  
manyetik rezonans  
görüntüleme, 181-184  
Bruselloz 102-105

#### D

Depresyon, 32-37, 189-194  
Devic sendromu, 204-207  
Disferlinopati, 45-50  
Disiplinler arası iletişim, 7-16  
Dopamin, 65-75

#### E-F

Epilepsi, 17-31, 51-54, 55-57,  
106-109, 189-194  
depresyon, 189-194  
kaygı, 189-194  
orgazm, 51-54  
refleks, 51-54  
Fasiyal paralizi, 122-123  
fiziksel aktivite, 32-37  
kulak, 122-123  
tedavi, 122-123

#### G-H

Görsel halüsinasyonlar, 143-149  
Hamartoma sendromu, 211-213  
manyetik rezonans  
görüntüleme, 211-213  
Herpes zoster virüs, 58-61, 200-203  
Hepatolitiküler dejenerasyon,  
150-153  
Hipokampus, 181-184  
manyetik rezonans  
görüntüleme, 181-184

#### I-İ

İlimli kognitif bozukluk, 181-184  
manyetik rezonans  
görüntüleme, 181-184

İnme, 76-82, 83-89, 106-109  
üst ekstremite, 83-89  
İnternal karotis arter inklüzyonu,  
106-109  
Homosistinüri, 106-109  
İshal, 76-82  
İskemi/reperfüzyon, 131-136  
İskemik inme,  
etyoloji, 1-6  
sınıflandırma, 1-6

#### K-L

Kafeik asit fenetil ester, 131-136  
Karaciğer hastalıkları, 150-153  
Korpus kallosum, 214-215  
Kortikal gelişim anomalisi, 55-57  
Kraniyal sinir hastalıkları, 137-142  
Kronik inflamatuvar demiyelinizan,  
62-63  
manyetik rezonans  
görüntüleme, 62-63  
Leptin, 17-31  
Limb-Girdle musküler distrofi,  
45-50  
tip 2B, 45-50  
Lhermitte-Duclos hastalığı,  
211-213  
manyetik rezonans  
görüntüleme, 211-213  
Lökoensefalopati, 102-105

#### M

MELAS sendromu, 161-166  
elektroensefalografi, 161-166  
Metakromatik lökodistrofi,  
195-199  
Migren, 90-95  
ferritin, 90-95  
folik asit, 90-95  
vitamin B12, 90-95  
Miyelit, 200-203

manyetik rezonans  
görüntüleme, 200-203  
Miyoshi miyopati, 45-50  
Motor aktivite günlüğü-28,  
geçerlilik, 83-89  
güvenilirlik, 83-89  
Multipl miyelom, 157-160  
diplopi, 157-160  
Multipl skleroz, 38-44, 137-142,  
154-156, 185-188  
beyin sapı, 137-142  
diplopi, 154-156  
interferon-beta, 154-156  
relapsing-remitting, 38-44  
trombosit, 185-188  
uyandırılmış potansiyeller, 38-44

#### N-O

Nörolojik hastalıklar,  
anestetik madde, 125-130,  
173-180  
cerrahi, 125-130, 173-180  
hastalık yönetimi, 125-130,  
173-180  
perioperatif dönem, 125-130,  
173-180  
preoperatif periyot, 125-130,  
173-180  
Nörosifiliz, 96-101,  
seftriakson, 96-101  
Nörosistiserkozis,  
fenitoin, 167-170  
nöbetler, 167-170  
Nütrisyon,  
enteral, 76-82  
ishal, 76-82  
Obezite, 17-31  
Oksidatif stres, 131-136

#### P-R

Parkinson hastalığı, 65-75,  
143-149, 150-153

dopamin, 65-75  
dürtü kontrol bozukluğu, 65-75  
karaciğer hastalıkları, 150-153  
kognisyon, 143-149  
uyandırılmış potansiyeller,  
143-149  
Perivasküler boşluk, 171-172  
manyetik rezonans  
görüntüleme, 171-172  
Plazmasitoma, 157-160  
Pnömoni, 76-82  
POEMS sendromu,  
radyoloji, 110-118  
sonuç, 110-118  
tedavi, 110-118  
Polinöropati, 110-118  
Poliradikülönöropati, 62-63  
manyetik rezonans  
görüntüleme, 62-63  
Radius yokluğu sendromu, 55-57  
Ramsay Hunt sendromu, 58-61,  
122-123

## S

Sağırlık, 102-105  
Seftriakson, 96-101  
Serebellum, 171-172  
Sinüs trombozu, 204-207  
Sistemik lupus eritematozus,  
204-207  
Spastik paropleji, 119-121,  
214-215  
herediter, 119-121, 214-215  
Spinal sinir kökleri, 62-63  
Subakut sklerozan panensefalit,  
161-166  
elektroensefalografi, 161-166

## T

Topiramet, 17-31  
Transkraniyal manyetik  
stimülasyon, 119-121  
Trombosit aktivasyonu, 185-188  
Trombositopeni, 55-57

Tüberküloz menenjit, 208-210  
işitme kaybı, 208-210  
sensörinöral, 208-210  
Türkiye, 7-16  
bakım kalitesi, 7-16

## U-Y

Uyandırılmış potansiyeller, 38-44,  
143-149  
Uyku apne, 32-37  
obstrüktif, 32-37  
Valproik asit, 17-31  
Ven trombozu, 58-61  
Yoğun bakım ünitesi, 7-16  
uzmanlaşma, 7-16

**17. Cilt Dizini**  
**17<sup>th</sup> Volume Index**

**SUBJECT INDEX**  
**(March 2011-December 2011)**

**A-B**

Alzheimer disease, 181-184  
magnetic resonance imaging,  
181-184  
Brucellosis, 102-105

**C**

Caffeic acid phenethyl ester,  
131-136  
Ceftriaxone, 96-101  
Cerebellum, 171-172  
Chronic inflammatory  
demyelinating, 62-63  
magnetic resonance imaging,  
62-63  
Corpus callosum, 214-215  
Cranial nerve diseases, 137-142

**D**

Deafness, 102-105  
Depression, 32-37, 189-194  
Devic's syndrome, 204-207  
Diarrhea, 76-82  
Dopamine, 65-75  
Dysferlinopathy, 45-50

**E-F**

Epilepsy, 17-31, 51-54, 55-57,  
106-109, 189-194  
anxiety, 189-194  
depression, 189-194  
orgasm, 51-54  
reflex, 51-54  
Evoked potentials, 38-44, 143-149  
Facial paralysis, 122-123  
ear, 122-123  
physical activity, 32-37  
therapeutics, 122-123

**H-I**

Hamartoma syndrome, 211-213  
magnetic resonance imaging,  
211-213

Hepatolenticular degeneration,  
150-153  
Herpes zoster virus, 58-61, 200-203  
Hippocampus, 181-184  
magnetic resonance imaging,  
181-184  
Intensive care units, 7-16  
specialization, 7-16  
Interdisciplinary communication,  
7-16  
Internal carotid artery occlusion,  
106-109  
homocystinuria, 106-109  
Ischemia/reperfusion, 131-136  
Ischemic stroke,  
classification, 1-6  
etiology, 1-6

**L**

Leptin, 17-31  
Leukoencephalopathies, 102-105  
Lhermitte-Duclos disease 211-213  
magnetic resonance imaging,  
211-213,  
Limb-Girdle muscular dystrophy,  
45-50  
type 2B, 45-50  
Liver diseases, 150-153

**M**

Malformations of cortical  
development, 55-57  
MELAS syndrome, 161-166  
electroencephalography,  
161-166  
Metachromatic leukodystrophy,  
195-199  
Migraine disorders, 90-95  
ferritins, 90-95  
folic acid, 90-95  
vitamin B12, 90-95

Mild cognitive impairment, 181-184  
magnetic resonance imaging,  
181-184  
Miyoshi myopathy, 45-50  
Motor activity log-28,  
reliability and validity, 83-89  
Multiple myeloma, 157-160  
diplopia, 157-160  
Multiple sclerosis, 38-44, 137-142,  
154-156, 185-188  
brain stem, 137-142  
diplopia, 154-156  
evoked potentials, 38-44  
interferon-beta, 154-156  
platelets, 185-188  
relapsing-remitting, 38-44  
Myelitis, 200-203  
magnetic resonance imaging,  
200-203

**N-O**

Neurocysticercosis,  
phenytoin, 167-170  
seizures, 167-170  
Neurologic disease,  
anesthetics, 125-130, 173-180  
disease management, 125-130,  
173-180  
perioperative period, 125-130,  
173-180  
preoperative period, 125-130,  
173-180  
surgery, 125-130, 173-180  
Neurosypphilis, 96-101  
ceftriaxone, 96-101  
Nutrition,  
diarrhea, 76-82  
enteral, 76-82  
Obesity, 17-31  
Oxidative stres, 131-136

- 
- P-R**
- Parkinson disease, 65-75, 143-149, 150-153
    - cognition, 143-149
    - dopamine, 65-75
    - evoked potentials, 143-149
    - impulse control disorders, 65-75
    - liver diseases, 150-153
  - Perivascular space, 171-172
    - magnetic resonance imaging, 171-172
  - Plasmacytoma, 157-160
  - Platelet activation, 185-188
  - Pneumonia, 76-82
  - POEMS syndrome, 110-118
    - radiology, 110-118
    - treatment outcome, 110-118
  - Polyneuropathies, 110-118
  - Polyradiculoneuropathy, 62-63
    - magnetic resonance imaging, 62-63
  - Ramsay Hunt syndrome, 58-61, 122-123
- S**
- Sinus thrombosis, 204-207
  - Sleep apnea, 32-37
    - obstructive, 32-37
  - Spastic paraplegia, 119-121, 214-215
    - hereditary, 119-121, 214-215
  - Spinal nerve roots, 62-63
  - Stroke, 76-82, 83-89, 106-109
    - upper extremity, 83-89
  - Subacute sclerosing panencephalitis, 161-166
    - electroencephalopathy, 161-166
  - Systemic lupus erythematosus, 204-207
- T**
- Thrombocytopenia absent radius syndrome, 55-57
  - Topiramate, 17-31
  - Transcranial magnetic stimulation, 119-121
  - Tuberculosis meningitis, 208-210
    - hearing loss, 208-210
    - sensorineural, 208-210
  - Turkey, 7-16
  - quality of health care, 7-16
- V**
- Valproic acid, 17-31
  - Vein thrombosis, 58-61
  - Visual hallucinations, 143-149